{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T18:18:57Z","timestamp":1795112337269,"version":"4.10.3"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T00:00:00Z","timestamp":1594771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T00:00:00Z","timestamp":1594771200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Sodium-glucose co-transporter-2 (SGLT-2) inhibitors are a relatively novel class of oral medications for the treatment of Type 2 DM with a generally acceptable safety profile. However, these agents have been associated with rare events of a serious and potentially life-threatening complication named euglycemic diabetic ketoacidosis (euDKA). euDKA is not identical with the typical diabetic ketoacidosis, as it often presents with serious metabolic acidosis but only mild to moderate glucose and anion gap elevation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>We report a case of a 51-year old female with Type 2 DM treated with an SGLT-2 inhibitor, developing severe metabolic acidosis with only mild blood glucose elevation after a routine surgery. A careful evaluation of involved factors led to the diagnosis of euDKA, followed by cautious application of simple therapeutic measures that resulted in complete restoration of acidosis and glycemic control in less than 48-h.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Euglycemic ketoacidosis is a rare but rather serious complication of SGLT-2 inhibitors use, often with a multifactorial etiology. Its atypical presentation requires a high level of awareness by physicians as early recognition of this complication can quickly and safely restore acid-base balance.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12882-020-01930-6","type":"journal-article","created":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T12:02:48Z","timestamp":1594814568000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Severe euglycemic diabetic ketoacidosis of multifactorial etiology in a type 2 diabetic patient treated with empagliflozin: case report and literature review"],"prefix":"10.1186","volume":"21","author":[{"given":"Erasmia","family":"Sampani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9174-4018","authenticated-orcid":false,"given":"Pantelis","family":"Sarafidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chrysostomos","family":"Dimitriadis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efstratios","family":"Kasimatis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitra","family":"Daikidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Bantis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexios","family":"Papanikolaou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aikaterini","family":"Papagianni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,15]]},"reference":[{"issue":"7","key":"1930_CR1","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.2337\/dc09-9032","volume":"32","author":"AE Kitabchi","year":"2009","unstructured":"Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN. Hyperglycemic crises in adult patients with diabetes. Diabetes Care. 2009;32(7):1335\u201343.","journal-title":"Diabetes Care"},{"issue":"5866","key":"1930_CR2","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1136\/bmj.2.5866.578","volume":"2","author":"JF Munro","year":"1973","unstructured":"Munro JF, Campbell IW, McCuish AC, Duncan LJ. Euglycaemic diabetic ketoacidosis. Br Med J. 1973;2(5866):578\u201380.","journal-title":"Br Med J"},{"issue":"4","key":"1930_CR3","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/BF00569937","volume":"30","author":"D Jenkins","year":"1993","unstructured":"Jenkins D, Close CF, Krentz AJ, Nattrass M, Wright AD. Euglycaemic diabetic ketoacidosis: does it exist? Acta Diabetol. 1993;30(4):251\u20133.","journal-title":"Acta Diabetol"},{"issue":"2","key":"1930_CR4","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1093\/ndt\/gfy407","volume":"34","author":"P Sarafidis","year":"2019","unstructured":"Sarafidis P, Ferro CJ, Morales E, et al. SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA. Nephrol Dial Transplant. 2019;34(2):208\u201330.","journal-title":"Nephrol Dial Transplant"},{"key":"1930_CR5","volume-title":"FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood","author":"FDA Drug Safety Communication","year":"2015","unstructured":"FDA Drug Safety Communication. FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood. 2015 (https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm446845.htm). Assessed July 20, 2019."},{"key":"1930_CR6","unstructured":"FDA Drug Safety Communication: FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections (https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm475463.htm). Assessed July 20, 2019."},{"issue":"22","key":"1930_CR7","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117\u201328.","journal-title":"N Engl J Med"},{"issue":"7","key":"1930_CR8","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644\u201357.","journal-title":"N Engl J Med"},{"issue":"23","key":"1930_CR9","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1056\/NEJMc1701990","volume":"376","author":"M Fralick","year":"2017","unstructured":"Fralick M, Schneeweiss S, Patorno E. Risk of diabetic ketoacidosis after initiation of an SGLT2 inhibitor. N Engl J Med. 2017;376(23):2300\u20132.","journal-title":"N Engl J Med"},{"issue":"1","key":"1930_CR10","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/ncpneph0073","volume":"2","author":"M Emmett","year":"2006","unstructured":"Emmett M. Anion-gap interpretation: the old and the new. Nat Clin Pract Nephrol. 2006;2(1):4\u20135.","journal-title":"Nat Clin Pract Nephrol"},{"key":"1930_CR11","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/978-1-4757-0734-2_4","volume":"111","author":"JD McGarry","year":"1979","unstructured":"McGarry JD, Foster DW. Hormonal control of ketogenesis. Adv Exp Med Biol. 1979;111:79\u201396.","journal-title":"Adv Exp Med Biol"},{"issue":"6","key":"1930_CR12","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1056\/NEJMra1503102","volume":"373","author":"BF Palmer","year":"2015","unstructured":"Palmer BF, Clegg DJ. Electrolyte and Acid-Base disturbances in patients with diabetes mellitus. N Engl J Med. 2015;373(6):548\u201359.","journal-title":"N Engl J Med"},{"issue":"6","key":"1930_CR13","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1016\/j.jdiacomp.2016.05.008","volume":"30","author":"BF Palmer","year":"2016","unstructured":"Palmer BF, Clegg DJ, Taylor SI, Weir MR. Diabetic ketoacidosis, sodium glucose transporter-2 inhibitors and the kidney. J Diabetes Complicat. 2016;30(6):1162\u20136.","journal-title":"J Diabetes Complicat"},{"issue":"2","key":"1930_CR14","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/jdi.12401","volume":"7","author":"W Ogawa","year":"2016","unstructured":"Ogawa W, Sakaguchi K. Euglycemic diabetic ketoacidosis induced by SGLT2inhibitors: possible mechanism and contributing factors. J Diabetes Investig. 2016;7(2):135\u20138.","journal-title":"J Diabetes Investig"},{"issue":"5","key":"1930_CR15","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.2337\/db15-1356","volume":"65","author":"E Ferrannini","year":"2016","unstructured":"Ferrannini E, Baldi S, Frascerra S, et al. Shift to fatty substrate utilization in response to sodium-glucose Cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes. Diabetes. 2016;65(5):1190\u20135.","journal-title":"Diabetes."},{"issue":"6","key":"1930_CR16","doi-asserted-by":"publisher","first-page":"771","DOI":"10.2337\/dc16-2724","volume":"40","author":"E Ferrannini","year":"2017","unstructured":"Ferrannini E, Baldi S, Frascerra S, et al. Renal handling of ketones in response to sodium-glucose Cotransporter 2 inhibition in patients with type 2 diabetes. Diabetes Care. 2017;40(6):771\u20136.","journal-title":"Diabetes Care"},{"issue":"8","key":"1930_CR17","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1210\/jc.2015-1884","volume":"100","author":"SI Taylor","year":"2015","unstructured":"Taylor SI, Blau JE, Rother KI. SGLT2 inhibitors may predispose to ketoacidosis. J Clin Endocrinol Metab. 2015;100(8):2849\u201352.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1930_CR18","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/nm.3828","volume":"21","author":"C Bonner","year":"2015","unstructured":"Bonner C, Kerr-Conte J, Gmyr V, et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med. 2015;21(5):512\u20137.","journal-title":"Nat Med"},{"issue":"1","key":"1930_CR19","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/s41467-019-08466-w","volume":"10","author":"RJ Perry","year":"2019","unstructured":"Perry RJ, Rabin-Court A, Song JD, et al. Dehydration and insulinopenia are necessary and sufficient for euglycemic ketoacidosis in SGLT2 inhibitor-treated rats. Nat Commun. 2019;10(1):548.","journal-title":"Nat Commun"},{"key":"1930_CR20","doi-asserted-by":"crossref","unstructured":"Sampani E, Sarafidis P, Papagianni A. Euglycaemic diabetic ketoacidosis as a complication of SGLT-2 inhibitors: epidemiology, pathophysiology and treatment. Expert Opin Drug Saf. 2020; (e pub ahead of print).","DOI":"10.1080\/14740338.2020.1764532"},{"issue":"12","key":"1930_CR21","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1016\/j.clinthera.2016.11.002","volume":"38","author":"RM Goldenberg","year":"2016","unstructured":"Goldenberg RM, Berard LD, Cheng AYY, Gilbert JD, Verma S, Woo VC, et al. SGLT2 inhibitor-associated diabetic ketoacidosis: clinical review and recommendations for prevention and diagnosis. Clin Ther. 2016;38(12):2654\u201364 e1.","journal-title":"Clin Ther"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-020-01930-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-020-01930-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-020-01930-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,14]],"date-time":"2021-07-14T23:14:46Z","timestamp":1626304486000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-020-01930-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,15]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1930"],"URL":"https:\/\/doi.org\/10.1186\/s12882-020-01930-6","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,15]]},"assertion":[{"value":"20 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written consent for publication was obtained from the patient.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors disclose that they don\u2019t have any financial or other relationships, which might lead to a conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"276"}}